Franklin Resources Inc. raised its holdings in Sanofi (NASDAQ:SNY - Free Report) by 10.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,776,982 shares of the company's stock after buying an additional 369,530 shares during the period. Franklin Resources Inc. owned approximately 0.15% of Sanofi worth $182,164,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in Sanofi in the fourth quarter valued at approximately $135,933,000. Boston Partners increased its position in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC raised its holdings in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after purchasing an additional 1,705,148 shares in the last quarter. DAVENPORT & Co LLC raised its holdings in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its position in shares of Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock worth $93,774,000 after purchasing an additional 514,542 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Stock Performance
Shares of SNY stock traded up $0.67 during mid-day trading on Thursday, hitting $54.62. 1,842,025 shares of the stock were exchanged, compared to its average volume of 2,279,558. The stock's fifty day simple moving average is $55.38 and its two-hundred day simple moving average is $52.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The stock has a market capitalization of $138.62 billion, a price-to-earnings ratio of 21.94, a P/E/G ratio of 1.01 and a beta of 0.58.
Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, analysts forecast that Sanofi will post 4.36 EPS for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on SNY shares. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.50.
Check Out Our Latest Stock Analysis on SNY
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
